Pathogenesis of Psoriasis and Current Challenges

Prinz J . The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003; 17:257–270.

Understanding psoriasis. Ottawa: Canadian Dermatology Association, 2004.

Lebwohl M . Psoriasis. Lancet 2003; 361:1197–1204.

Elder J Nair R Henseler T . The genetics of psoriasis 2001. Arch Dermatol 2001; 137:1447–1454.

National Psoriasis Foundation 2001 Benchmark Survey on Psoriasis and Psoriatic Arthritis. Portland, OR, National Psoriasis Foundation, 2001.

Krueger J . The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46:1–23.

Chaudhari U Romano P Mulcahy LD . Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet 2001; 357:1842–1847.

Gordon K . Targeting the pathogenesis of psoriasis with biologics. Skin Allergy News 2003; Suppl:4–5.

Friedrich M Kramming S Henze M . Flow cytometric characterization of lesional T cells in psoriasis: Intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res 2000; 292:519–521.

Austin LM Ozawa M Kikuchi T . The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 13:752–759.

Gottlieb A . Immunobiologicals for psoriasis: Using targeted immunotherapies as pathogenic probes in psoriasis. In: Weinstein GD Gottlieb AB , eds. Therapy of Moderate-to-Severe Psoriasis. New York: Marcel Dekker, 2003; pp 239–260.

Griffiths C . The immunological basis of psoriasis. J Eur Acad Dermatol Venereol 2003; 17:1–5.

Krueger J Ellis C . Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol 2003; 148:784–788.

Koo J Lebwohl M . Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41:51–59.

Georgala S Koumantaki E Rallis E . Generalized pustular psoriasis developing during withdrawal of short-term cyclosporin therapy. Br J Dermatol 2000; 142:1057.

Feldman SR Menter A Koo JY . Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004; 150:317–326.

Choi J Koo Y . Quality of life issues in psoriasis. J Am Acad Dermatol 2003; 19:S57–S61.

Weiss S Kimball A Liewehr D . Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 47:512–518.

Gupta M Gupta A . Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139:846–850.

Feldman S Fleischer A Reboussin D . The economic impact of psoriasis inceases with psoriasis severity. J Am Acad Dermatol 1997; 37:564–569.

Finlay A Coles E . The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132:236–244.

Gupta M Gupta A . Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol 1995; 34:700–703.

Weisman S Pollack C Gottschalk R . Psoriasis disease severity measures: Comparing efficacy of treatments for severe psoriasis. J Dermatol Treat 2003; 14:158–165.

Ashcroft D Po A Wan Williams H . Clinical measures of disease severity and outcome in psoriasis: A critical appraisal of their quality. Br J Dermatol 1999; 141:185–191.

Yune Y Park S Oh HS . Objective assessment of involved surface area in patients with psoriasis. Skin Res Technol 2003; 9:339–342.

Carlin C Feldman SR Krueger JG . A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis (in press). J Am Acad Dermatol 2004; 50:859–866.

Menter MA Krueger GC Feldman SR . Psoriasis treatment 2003 at the new millennium: Position paper on behalf of the authors. J Am Acad Dermatol 2003; 49:S39–S43.

Lebwohl M Mentor A Koo J Feldman S . Case studies in severe psoriasis: A clinical strategy. J Dermatol Treat 2003; 14:26–46.

Lebwohl M . New developments in the treatment of psoriasis. Arch Dermatol 2002; 138:686–689.

Linden K Weinstein G . Psoriasis: Current perspectives with an emphasis on treatment. Am J Med 1999; 107:595–605.

National Psoriasis FoundationTherapy for Moderate to Severe Psoriasis. Marcel Dekker, New York, 2003.

Prodanovich S Kirsner R Taylor R . Treatment of patients hospitalized for psoriasis. Dermatol Clin 2000; 18:425–435.

Armstrong RB Leach EE Fleiss JL . Modified Goeckerman therapy for psoriasis. A two-year follow-up of a combined hospital-ambulatory care program. Arch Dermatol 1984; 120:313–318.

Geilen C Orfanos C . Standard and innovative therapy of psoriasis. Clin Exp Rheumatol 2002; 20:S81–S87.

British Photodermatology Group guidelines for PUVA. Br J Dermatol 1994; 130:246–255.

Lebwohl M . Combining the new biologic agents with our current psoriasis armamentarium. J Am Acad Dermatol 2003; 49:S118–S124.